Skip to main content

Table 1 Main characteristics of the 753 leprosy patients from UMDT/CT-BR study in PB and MB cases stratified according to the development of leprosy reaction and other manifestations

From: Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil

  Number Sex
(F/M)
Age
(median, range)
R&J BI
(median,range)
BCG scar (presence of scar/total)
PB reaction-free 129 86/43 34 (9-65) 11 I/ 42TT/ 75 BT/ 1BB 0 (0-1.75) 66/129
PB with RR 13 8/5 38 (6-60) 3 TT/ 7 BT/ 3 BB 0 (0-2.6) 6/13
PB with neuritis 16 10/6 39 (11-63) 3 TT/ 12BT/1BB 0 (0-0.75) 7/16
MB reaction-free 206 91/115 43 (8-65) 115 BT/ 9 BB/ 44 BL/ 38 LL 0 (0-6) 106/206
MB with RR 153 35/118 43 (7-65) 30 BT/ 17 BB/106 BL 2.75 (0-6) 78/153
MB with ENL 48 16/32 33 (8-62) 15 BL/ 33 LL 4.5 (0.5-5.6) 23/48
MB with others CM 55 17/38 45 (11-65) 9 BT/ 3 BB/ 26 BL/ 17 LL 4 (0-6) 30/55
MB with neuritis 133 42/91 36 (10-64) 47 BT/ 7 BB/ 43 BL/ 36 LL 4 (0-5.75) 53/133
  1. PB Paucibacillary Leprosy, MB Multibacillary Leprosy, RR Reversal Reaction, ENL Erythema Nodosum Leprosum, CM clinical manifestations, n number, F female, M male, R & J Ridley & Jopling Classification, BI Bacilloscopic Index, BCG Bacillus Calmette Guérin vaccine. PB and MB leprosy cases classification was based on the number of skin lesions according to WHO operational classification system